Immunotherapy for Ewing sarcoma and DSRCT
Treatments studied
Part of Cancer clinical trials.
This trial tests a new immunotherapy that targets a specific protein change found in Ewing sarcoma and desmoplastic small round cell tumors (DSRCT). The therapy is designed to help your immune system recognize and attack cancer cells. It may be an option if you have already received standard chemotherapy and your tumor has a certain genetic marker.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have Ewing sarcoma or DSRCT with a specific genetic change (EWSR1 fusion) and have completed standard chemotherapy.
- Your immune system type (HLA) must match one of the immunotherapy targets.
- You may have no visible disease, small spots in the lung or bone, or measurable tumors.
- Your age must fit the current enrollment phase: adults first, then adolescents, then children.
- Your blood counts, liver, and kidney function must be within safe limits.
- You cannot be pregnant or breastfeeding, and must use contraception during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized radiation therapy that adjusts the dose based on your tumor. It aims to improve treatment for Ewing sarcoma while limiting side effects.
This trial tests new drugs for young people with Ewing sarcoma or similar sarcomas that have come back or not responded to standard treatment. The goal is to see if these drugs can shrink or control the cancer.
This trial is testing a new drug called xaluritamig for children, teens, and adults with Ewing sarcoma that has come back or is not responding to treatment. The goal is to see if this drug can shrink the cancer or stop it from growing.
This trial tests a targeted drug called trastuzumab deruxtecan for children and young adults with certain cancers that have come back or not responded to treatment. It may help if your tumor has not responded to standard therapies.
This trial tests a new drug called PEEL-224 combined with two chemotherapy drugs (vincristine and temozolomide) for people ages 12 to 49 with sarcoma that has come back or hasn't responded to standard treatments. The goal is to see if this combination is safe and effective.
This trial tests a combination of two chemotherapy drugs (lurbinectedin and irinotecan) for people with desmoplastic small round cell tumor (DSRCT) that has spread or cannot be removed by surgery. It is for patients whose cancer has gotten worse after at least one prior treatment.
Hear when a new Ewing Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.